Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study

References

• Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol. 2019;29(4):457–470. doi: 10.1016/j.euroneuro.2019.02.003.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. doi: 10.1111/bdi.12609.
   PubMed Web of Science ®Google Scholar
• Goodwin G, Haddad P, Ferrier I, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi: 10.1177/0269881116636545.
   PubMed Web of Science ®Google Scholar
• Parker GB, Graham RK, Tavella G. Is there consensus across international evidence‐based guidelines for the management of bipolar disorder? Acta Psychiatr Scand. 2017;135(6):515–526. doi: 10.1111/acps.12717.
   PubMed Web of Science ®Google Scholar
• Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ. 2014;349(5):g5673–g5673. doi: 10.1136/bmj.g5673.
   PubMedGoogle Scholar
• Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder. J Clin Psychiatry. 2010;71(3):296–303. doi: 10.4088/JCP.09m05514yel.
   PubMed Web of Science ®Google Scholar
• Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):351–359. doi: 10.1016/S2215-0366(14)70314-1.
   PubMed Web of Science ®Google Scholar
• Jawad I, Watson S, Haddad PM, et al. Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol. 2018;8(12):349–363. doi: 10.1177/2045125318804364.
   PubMed Web of Science ®Google Scholar
• Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry. 2008;9(3):219–224. doi: 10.1080/15622970701530917.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once monthly in the maintenance treatment of bipolar I disorder. J Clin Psychiatry. 2017;78(3):324–331. doi: 10.4088/JCP.16m11201.
   PubMed Web of Science ®Google Scholar
• Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr. 2006;11(12 Suppl 14):1–8. doi: 10.1017/S1092852900025852.
   PubMed Web of Science ®Google Scholar
• Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012;26(5):403–420. doi: 10.2165/11631310-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Woo YS, Jeong JH, Kang H, et al. Preventive effect of aripiprazole once-monthly on relapse into mood episodes in bipolar disorder: a multicenter, one-year, retrospective, mirror image study. J Affect Disord. 2024;351:381–386. doi: 10.1016/j.jad.2024.01.257.
   PubMed Web of Science ®Google Scholar
• Boyce P, Irwin L, Morris G, et al. Long‐acting injectable antipsychotics as maintenance treatments for bipolar disorder—a critical review of the evidence. Bipolar Disord. 2018;20 Suppl 2(S2):25–36. doi: 10.1111/bdi.12698.
   PubMedGoogle Scholar
• Bartoli F, Cavaleri D, Nasti C, et al. Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies. Ther Adv Psychopharmacol. 2023;13:20451253231163682. doi: 10.1177/20451253231163682.
   Web of Science ®Google Scholar
• Lähteenvuo M, Tanskanen A, Taipale H, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75(4):347–355. doi: 10.1001/jamapsychiatry.2017.4711.
   PubMed Web of Science ®Google Scholar
• Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics. Boston, MA: Pearson 2013).
   Google Scholar
• National Collaborating Centre for Mental Health (UK). Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. 2014.
   Google Scholar
• Bartoli F, Callovini T, Cavaleri D, et al. Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1579–1586. doi: 10.1007/s00406-022-01522-5.
   PubMed Web of Science ®Google Scholar
• Goto J, Shono M, Abe Y, et al. Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: a multicenter 1‐year retrospective mirror image study. Neuropsychopharmacol Rep. 2023;43(3):425–433. doi: 10.1002/npr2.12371.
   PubMed Web of Science ®Google Scholar
• Chan H-W, Huang C-Y, Feng W-J, et al. Clinical outcomes of long-acting injectable risperidone in patients with bipolar I disorder: a 1-year retrospective cohort study. J Affect Disord. 2016;205:360–364. doi: 10.1016/j.jad.2016.08.023.
   PubMed Web of Science ®Google Scholar
• Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol. 2012;22(11):825–835. doi: 10.1016/j.euroneuro.2012.03.004.
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Iwata N. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(9):pyw038. doi: 10.1093/ijnp/pyw038.
   PubMed Web of Science ®Google Scholar
• Hsieh MH, Chuang P-Y, Wu C-S, et al. Bipolar patients treated with long-acting injectable risperidone in Taiwan: a 1-year mirror-image study using a national claims database. J Affect Disord. 2017;218:327–334. doi: 10.1016/j.jad.2017.04.074.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2007;434(434):50–56. doi: 10.1111/j.1600-0447.2007.01059.x.
   Google Scholar
• Prajapati AR, Wilson J, Song F, et al. Second‐generation antipsychotic long‐acting injections in bipolar disorder: systematic review and meta‐analysis. Bipolar Disord. 2018;20(8):687–696. doi: 10.1111/bdi.12707.
   PubMed Web of Science ®Google Scholar
• Magalhães PV, Dodd S, Nierenberg AA, et al. Cumulative morbidity and prognostic staging of illness in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Aust N Z J Psychiatry. 2012;46(11):1058–1067. doi: 10.1177/0004867412460593.
   PubMed Web of Science ®Google Scholar
• Tremain H, Fletcher K, Murray G. Number of episodes in bipolar disorder: the case for more thoughtful conceptualization and measurement. Bipolar Disord. 2020;22(3):231–244. doi: 10.1111/bdi.12872.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Hellmund G, Geddes JR, et al. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199(1):57–63. doi: 10.1192/bjp.bp.110.084822.
   PubMed Web of Science ®Google Scholar
• Hayes JF, Marston L, Walters K, et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records. World Psychiatry. 2016;15(1):53–58. doi: 10.1002/wps.20298.
   PubMed Web of Science ®Google Scholar
• Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta-review of the scientific literature. Bipolar Disord. 2017;19(7):575–586. doi: 10.1111/bdi.12543.
   PubMed Web of Science ®Google Scholar
• Macneil CA, Hasty MK, Berk M, et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry. 2011;5(2):100–107. doi: 10.1111/j.1751-7893.2011.00273.x.
   PubMed Web of Science ®Google Scholar
• Tohen M, Zarate CA, Hennen J, et al. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099–2107. doi: 10.1176/appi.ajp.160.12.2099.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Grunze H, Vieta E, et al. The international college of NeuroPsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2016;20(2):180–195. doi: 10.1093/ijnp/pyw109.
   Web of Science ®Google Scholar